Collaboration, License and Option Agreements - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended		36 Months Ended
	Nov. 18, 2021	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date				2019-04
Liability to licensor		$ 19,806	$ 19,806
BeiGene
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Amendment Date				2021-11
Upfront Non-Refundable Payment				$ 25,000
Revenues		0
License termination information, Description	In the event the license is terminated, the liability will be extinguished with no further payment to BeiGene.
Current portion of deferred revenue	$ 19,800
Liability to licensor		19,800	19,800
Context Therapeutics Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues		11,000	$ 0
Maximum Potential Aggregate Payments		$ 133,500